A Letter to the Editor Regarding ‘Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-analysis Using the GRADE Framework’
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
A Letter to the Editor Regarding ‘Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-analysis Using the GRADE Framework’ ; volume:13 ; number:10 ; day:24 ; month:8 ; year:2024 ; pages:2203-2206 ; date:10.2024
Infectious diseases and therapy ; 13, Heft 10 (24.8.2024), 2203-2206, 10.2024
- Creator
-
Volkman, Hannah R.
Nguyen, Jennifer L.
Jodar, Luis
McLaughlin, John M.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40121-024-01019-9
- URN
-
urn:nbn:de:101:1-2412050706395.124271884602
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Volkman, Hannah R.
- Nguyen, Jennifer L.
- Jodar, Luis
- McLaughlin, John M.
- SpringerLink (Online service)
Other Objects (12)
Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex
Determinants of protective humoral response to mRNA-1273 and BNT162b2 vaccines in peritoneal dialysis patients: a prospective cohort study
Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework
A Response to: A Letter to the Editor Regarding ‘Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework’
Correction to: Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework
Immunogenicity of mRNA-1273 and BNT162b2 in Immunocompromised Patients: Systematic Review and Meta-analysis Using GRADE
Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S
Letter to the Editor Regarding: “Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults”
Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination
mRNA vaccines: A lucky shot?
A Response to: Letter to the Editor Regarding “Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults”
Human leukocyte antigen variants associate with BNT162b2 mRNA vaccine response
Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex
Determinants of protective humoral response to mRNA-1273 and BNT162b2 vaccines in peritoneal dialysis patients: a prospective cohort study
Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework
A Response to: A Letter to the Editor Regarding ‘Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework’
Correction to: Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework
Immunogenicity of mRNA-1273 and BNT162b2 in Immunocompromised Patients: Systematic Review and Meta-analysis Using GRADE
Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S
Letter to the Editor Regarding: “Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults”
Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination
mRNA vaccines: A lucky shot?
A Response to: Letter to the Editor Regarding “Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults”
Human leukocyte antigen variants associate with BNT162b2 mRNA vaccine response
Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex
Determinants of protective humoral response to mRNA-1273 and BNT162b2 vaccines in peritoneal dialysis patients: a prospective cohort study
Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework
A Response to: A Letter to the Editor Regarding ‘Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework’
Correction to: Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework
Immunogenicity of mRNA-1273 and BNT162b2 in Immunocompromised Patients: Systematic Review and Meta-analysis Using GRADE
Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S
Letter to the Editor Regarding: “Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults”
Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination
mRNA vaccines: A lucky shot?
A Response to: Letter to the Editor Regarding “Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults”